Plain-English translation of NCT07315854 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of two immunotherapy drugs called given together with standard chemotherapy (S-1 and oxaliplatin) for patients with advanced or metastatic stomach cancer or cancer at the junction between the stomach and esophagus who have never received prior systemic treatment. The goal is to see whether adding this new immunotherapy to chemotherapy can help more patients respond to treatment and live longer. This is an early-stage trial enrolling about 32 patients.
Currently, patients with advanced stomach cancer have limited treatment options and poor outcomes. This medication is designed to help the immune system recognize and attack cancer cells more effectively when combined with chemotherapy, potentially offering patients a new way to fight this serious disease.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will have a 3-week screening period with blood tests and imaging scans. Then you will receive treatment in 3-week cycles: two immunotherapy infusions and a chemotherapy infusion on day 1, plus an oral chemotherapy pill taken twice daily for 14 days followed by a 7-day break. This induction phase continues for 6 cycles (about 18 weeks). If your cancer responds or stays stable and you tolerate the treatment well, you will continue with a maintenance phase where you receive only the immunotherapy and oral chemotherapy (without the infused chemotherapy) until your cancer progresses or you experience unacceptable side effects. You will have tumor imaging scans every 6 weeks for the first 24 weeks, then every 9 weeks afterward.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
China